Risk of Noncardiac Surgery After TAVR

Suboptimal TAVR prosthesis function was associated with adverse outcomes.

As transcatheter aortic valve replacement (TAVR) volumes continue to grow, the need for noncardiac surgery after TAVR will increase, but the risks and optimal timing of noncardiac surgery in these patients are unknown.

In this single-center cohort study, researchers examined risk for a composite adverse event (death, stroke, myocardial infarction, and major bleeding) after noncardiac surgery by time since TAVR and other surgical factors among 300 patients (mean age, 82 years; 48% women). Surgeries included elective (160 patients) and urgent or emergent (140 patients), occurring within 30 days of TAVR in 21%, at 31–180 days in 25%, 181–365 days in 23%, and more than 1 year later in 31%. Surgery type was classified as low risk (7%), intermedia…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)